– Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU
– ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a low drug-related diarrhea rate
– Data submitted to support use across wide age range of patients, including those with JAG1 and NOTCH2 mutations
BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare…
